Chugai Pharmaceutical Co., Ltd. (TYO:4519)
Japan · Delayed Price · Currency is JPY | Market Cap | 11.18T -5.1% |
| Revenue (ttm) | 1.34T +12.3% |
| Net Income | 471.37B +19.2% |
| EPS | 286.42 +19.2% |
| Shares Out | 1.65B |
| PE Ratio | 23.72 |
| Forward PE | 20.16 |
| Dividend | 132.00 (1.94%) |
| Ex-Dividend Date | Dec 29, 2026 |
| Volume | 5,542,700 |
| Open | 6,773.00 |
| Previous Close | 6,614.00 |
| Day's Range | 6,710.00 - 6,888.00 |
| 52-Week Range | 5,974.00 - 10,700.00 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 8,656.67 (+27.4%) |
| Earnings Date | Oct 27, 2026 |
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular... [Read more]
Financial Performance
In 2025, Chugai Pharmaceutical's revenue was 1.26 trillion, an increase of 7.46% compared to the previous year's 1.17 trillion. Earnings were 434.01 billion, an increase of 12.06%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for 4519 stock is "Buy." The 12-month stock price target is ¥8,657, which is an increase of 27.40% from the latest price.
News
Chugai Pharmaceutical Co., - Depositary Receipt Price Target Decreased by 15.22% to $26.89
The average one-year price target for Chugai Pharmaceutical Co., - Depositary Receipt (OTCPK:CHGCY) (MUN:CUP0) has been revised to $26.89 / share. This is a decrease of 15.22% from the prior estimate ...
Chugai Regains Rights To Emugrobart, Shifts Focus Back To SMA Development
(RTTNews) - Chugai Pharmaceutical Co., Ltd. (4519) announced that development of Emugrobart (GYM329) for obesity has been discontinued, with all rights to the drug being returned by Roche (RHHBY).
Chugai Pharmaceutical Earnings Call Transcript: Q2 2026
Revenue and profit rose sharply in H1 FY 2026, driven by strong product sales, royalties, and one-time income. Pipeline progress and a record number of regulatory filings support a positive outlook, while strategic investments and a stable dividend policy continue.
Chugai Pharmaceutical Quarterly report: Q2 2026
Chugai Pharmaceutical has published its Q2 2026 quarterly earnings report on July 24, 2026.
Chugai Pharmaceutical Slides: Q2 2026
Chugai Pharmaceutical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 24, 2026.
Chugai Pharmaceutical Earnings Call Transcript: Q1 2026
Q1 FY2026 delivered double-digit growth in revenue and profit, driven by strong Hemlibra and Nemluvio exports, new product launches, and increased royalty income. Performance was in line with expectations, with positive FX impact and robust pipeline progress.
Chugai Pharmaceutical Quarterly report: Q1 2026
Chugai Pharmaceutical has published its Q1 2026 quarterly earnings report on April 24, 2026.
Chugai Pharmaceutical Slides: Q1 2026
Chugai Pharmaceutical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 24, 2026.
Japanese drugmakers slump after Trump unveils discount drug website
Shares of Japanese pharmaceutical companies slumped in early Tokyo trading on Friday after U.S. President Donald Trump's website offering discounted prescription medicines went live.
Chugai Pharmaceutical Earnings Call Transcript: Q4 2025
Record FY2025 results with revenue up 7.5% and core operating profit up 12.1%, driven by strong exports and domestic growth. FY2026 guidance projects further record highs, with robust pipeline progress and increased dividends.
Chugai Pharmaceutical Quarterly report: Q4 2025
Chugai Pharmaceutical has published its Q4 2025 quarterly earnings report on January 29, 2026.
Chugai Pharmaceutical Slides: Q4 2025
Chugai Pharmaceutical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 29, 2026.
Chugai Pharmaceutical Annual report: Q4 2025
Chugai Pharmaceutical has published its Q4 2025 annual report on January 29, 2026.
Chugai Pharmaceutical Slides: Investor Update
Chugai Pharmaceutical has posted slides in relation to its latest quarterly earnings report, which was published on November 27, 2025.
Chugai Pharmaceutical Earnings Call Transcript: Q3 2025
Q3 FY2025 delivered strong revenue and profit growth, driven by robust domestic and overseas sales, especially from Hemlibra, Actemra, and new product launches. Strategic acquisitions and pipeline progress support a positive outlook, with full-year results expected to exceed last year.
Chugai Pharmaceutical Quarterly report: Q3 2025
Chugai Pharmaceutical has published its Q3 2025 quarterly earnings report on October 24, 2025.
Chugai Pharmaceutical Slides: Q3 2025
Chugai Pharmaceutical has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 24, 2025.